AbbVie reported $73M in Interest Income for its fiscal quarter ending in March of 2025.


Interest Income Change Date
AbbVie USD 73M 19M Mar/2025
Abbott USD 71M 11M Jun/2025
ALKERMES USD 11.09M 949K Jun/2025
AstraZeneca 68M 16M Jun/2025
Biogen USD 32.3M 8.4M Jun/2025
BioMarin Pharmaceutical USD 18.83M 186K Jun/2025
Eisai 3.11B 783M Mar/2024
Eli Lilly USD 40M 8.3M Jun/2025
Gilead Sciences 73M 21M Jun/2025
GlaxoSmithKline 50M 4M Jun/2025
J&J 332M 51M Mar/2025
Medtronic USD 114M 23M Jan/2025
Merck USD 109M 37M Mar/2025
Pacira USD 5.01M 1.89M Jun/2025
Pfizer USD 156M 13M Jun/2025
Regeneron Pharmaceuticals 174.8M 1.3M Jun/2025
Roche Holding 2M 12M Dec/2020
Sanofi 76M 10M Jun/2025
Ultragenyx Pharmaceutical USD 5.79M 1.04M Jun/2025
United Therapeutics USD 51.3M 200K Jun/2025
Vertex Pharmaceuticals USD 122.4M 1.5M Jun/2025
Zoetis 19M 4M Jun/2025